This study tests combinations of targeted drugs for advanced non-small cell lung cancer (NSCLC) with special gene changes called EGFR and MET. Capmatinib and osimertinib are kinase inhibitors. They stop signals that make cancer cells grow and spread. Ramucirumab is a monoclonal antibody that stops new blood vessels from forming, which tumors need to grow. These drugs may help shrink or control the cancer.
Patients will be divided into two groups. Group A gets capmatinib, osimertinib, and ramucirumab, while Group B gets just capmatinib and osimertinib. Both groups will have regular CT or MRI scans and blood tests.
- Duration: The study involves continuous treatment with regular scans and blood tests.
- Eligibility: You must have specific gene changes, be able to swallow pills, and meet other health criteria.
- Risks: Possible side effects include those typical of cancer treatments but are monitored throughout the study.
Talk to your doctor to see if this study might be right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand